"paper"

Gunhild Waldemar (GW): The ageing European population and the steep rise in people affected by Alzheimer’s Disease bring the EADC at the forefront of scientific research. Can you briefly introduce the EADC and its structure to the readers of EANpages? Bengt Winblad (BW): The EADC (European Alzheimer Disease Consortium) is a fully functional network of 66 European centres of clinical and biomedical research excellence, working and leading innovative research in the field of AD and related dementias (www.eadc.info).

by Elena Lebedeva I participated at the first part the Masters of Headache disorders program in Copenhagen and I passed the exam after that. Participants need to complete five more parts about: headache mechanisms, risk factors, diagnostics and treatment, including… Continue Reading

On Wednesday January 18th, the working groups of the Value of Treatment (VOT) project met to update on the work done and share the outcomes achieved.

The European Journal of Neurology continues to attract a considerable number of original submissions, and can only publish approximately 15% of those received. Articles cover a broad range of clinical and scientific topics within neurology, but the proportion of articles on a disease area generally corresponds to its prevalence.

Dear EAN members, dear readers, as EANpages Editor, it is my privilege to send you a few lines at the end of this 2016, which has been a very important and special year for EANpages. Together with the launch of… Continue Reading

It is a dream of neurologists to cure degenerative diseases. The big brothers, Alzheimer’s and Parkinson’s disease have always been a huge burden of the population but are now, in the millennium of increasing population age becoming a scourge of humanity. While everybody is acknowledging this, both PD (1) and AD (2) communities of clinician researchers and basic researchers are preparing to attack the problem fundamentally frequently unnoticed by the general neurology community.

It is a dream of neurologists to cure degenerative diseases. The big brothers, Alzheimers’ and Parkinsons’ disease have always been a huge burden of the population but are now, in the millennium of increasing population age becoming a scourge of humanity. While everybody is acknowledging this, both PD1 and AD2 communities of clinician researchers and basic researchers are preparing to attack the problem fundamentally frequently unnoticed by the general neurology community.